The study is a multicentre, double-blind, factorial (2x2) design in which patients will be randomised to one of four groups:
Group A : placebo / placebo
Group B : placebo / prednisolone
Group C : pentoxifylline / placebo
Group D : pentoxifylline / prednisolone
Patients entered into this trial will also be eligible for a number of associated sub-studies.
- A case-control study of prescribed medications and other precipitants in patients with alcoholic hepatitis.
- Genetic causes of alcoholic hepatitis.
- Steroid sensitivity sera study versus clinical scoring system to predict outcome.A global liver function assay study.
- Central pathology review.
- Health Economics.